

## South Korea-based SK Inc. invests \$350 M in ‘Centre for Breakthrough Medicines’

11 January 2022 | News

**The Centre for Breakthrough Medicines and SK Inc. are partnering to hire 2,000 advanced therapy experts and build the largest manufacturer of cell and gene therapies in the world**



The Centre for Breakthrough Medicines (CBM), based in the US, has received \$350 million in equity financing from South Korea-based SK Inc. CBM is partnering with SK to create the world's largest end-to-end cell and gene therapy contract development and manufacturing organization (CDMO).

CBM will leverage this investment to enhance its fully integrated pre-clinical through commercial manufacturing capabilities with world class automation and infrastructure. Existing and future capabilities include process development, viral vector manufacturing, cell processing, plasmid DNA, cell banking, and a full suite of complimentary analytical development and testing capabilities.

In addition to supporting lab and GMP suite build-out, this investment will also enable strategic joint ventures, sponsored research agreements, and development of proprietary technology platforms.